Vontobel Holding Ltd. bought a new position in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 33,097 shares of the company's stock, valued at approximately $1,594,000.
Other hedge funds have also modified their holdings of the company. SVB Wealth LLC purchased a new stake in shares of QIAGEN during the 1st quarter worth about $31,000. Farther Finance Advisors LLC lifted its stake in QIAGEN by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock valued at $51,000 after buying an additional 849 shares in the last quarter. Hilltop National Bank purchased a new position in QIAGEN in the 2nd quarter valued at about $66,000. ANTIPODES PARTNERS Ltd purchased a new position in QIAGEN in the 1st quarter valued at about $94,000. Finally, GAMMA Investing LLC lifted its stake in QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.
QIAGEN Stock Performance
NYSE:QGEN opened at $46.93 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock has a market capitalization of $10.43 billion, a P/E ratio of 27.73, a PEG ratio of 2.46 and a beta of 0.66. The company has a 50 day moving average price of $47.11 and a 200 day moving average price of $45.54. QIAGEN N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88.
QIAGEN (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company posted $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Equities research analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current year.
Analyst Ratings Changes
QGEN has been the topic of a number of research reports. Barclays set a $53.00 price target on shares of QIAGEN and gave the company an "overweight" rating in a research note on Thursday, October 2nd. Wall Street Zen lowered shares of QIAGEN from a "buy" rating to a "hold" rating in a research note on Saturday. Bank of America raised their price target on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. UBS Group increased their price objective on shares of QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Finally, Cowen reiterated a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, QIAGEN has an average rating of "Hold" and a consensus price target of $49.40.
Check Out Our Latest Stock Analysis on QGEN
About QIAGEN
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.